SignalFDA/Bio

FDA FAST TRACK PUTS ERASCA’S (ERAS) PANCREATIC BET CENTER STAGE - YAHOO

FDA fast-track designation accelerates ERAS’s pancreatic cancer drug development timeline.

What changed

FDA fast-track designation accelerates ERAS’s pancreatic cancer drug development timeline.

Why it matters

FDA fast-track designation accelerates ERAS’s pancreatic cancer drug development timeline. — impact context not separately stored; see What changed.

Sources